GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
Series GSE136149 Query DataSets for GSE136149
Status Public on Dec 02, 2019
Title Circulating miR 802-5p and miR 194-5p and brain expression of MEF2C as novel biomarkers of breast cancer brain metastasis
Organism Mus musculus
Experiment type Non-coding RNA profiling by high throughput sequencing
Summary We hypothesized that circulating miRNAs could work as biomarkers for early detection of breast cancer brain metastasis (BCBM), and their targets could constitute new targets for modulation. We used a mouse model of BCBM and Next-Generation Sequencing to establish the circulating miRNAs alterations along brain metastasis development and performed bioinformatics analysis to identify their targets with relevance in the metastatic process. We additionally analyzed human resected brain metastasis of breast cancer patients for target’s expression validation. In our mouse model, we observed a deregulation of circulating miRNAs profile during BCBM progression, with a downregulation of miR-802-5p and miR-194-5p in plasma prior to brain metastases detection. The transcription factor myocyte enhancer factor 2C (MEF2C), was identified as a target for both miRNAs, and its expression was increasingly observed in malignant cells along brain metastasis development. Its upregulation was also observed in peritumoral astrocytes and in human BCBM. Collectively, downregulation of circulating miR-802-5p and miR-194-5p appear as precocious biomarkers for BCBM and MEF2C emerges as a new player and a potential target for modulation.
Overall design We used a mouse model of breast cancer brain metastasis (BCBM), relying on the innoculation of breast cancer cells (or vehicle; control) in the carotid artery of Balb/c mouse, as a reliable model of brain metastasization of breast cancer, and collected brain and plasma samples at different time points (3, 7 and 10 days). Brain metastasis development was profiled by histologic analysis of brain sections and alterations in the circulating miRNA signature were determined by Next-Generation Sequencing miRNA analysis of plasma samples. MiRNAs with an aberrant expression prior to brain metastasis detection were selected for further study. This included the validation of their altered expression by qPCR and the identification of their potential targets with relevance for the metastatic process by bioinformatics analayis. Finnally, the expression of the most promising target was determined by immunofluorescence analysis of brain sections along metastasis development and the data obtained in the mouse model was further validated by analysis of ressected brain metastasis from breast cancer patients.
Contributor(s) Sereno M, Hásko J, Molnár K, Medina SJ, Reisz Z, Malhó R, Videira M, Tiszlavicz L, Booth SA, Wilhelm I, Krizbai IA, Brito MA
Citation(s) 31930767
Submission date Aug 21, 2019
Last update date Feb 05, 2020
Contact name Sarah Medina
Phone 204-789-7048
Organization name Public Health Agency of Canada
Department One Health
Street address 1015 Arlington Street
City WInnipeg
State/province Manitoba
ZIP/Postal code R3E 3R2
Country Canada
Platforms (1)
GPL16417 Illumina MiSeq (Mus musculus)
Samples (6)
GSM4041654 3-day-4T1
GSM4041655 3-day-control
GSM4041656 7-day-4T1
BioProject PRJNA561379
SRA SRP219024

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE136149_miRNA_reads_per_million_list.xlsx 56.1 Kb (ftp)(http) XLSX
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap